Kornimate/medical-research-clean huggingface dataset:
correlations of epigenetic changes with pocd in surgical patients

Conditions: Postoperative Cognitive Dysfunction

Summary: postoperative cognitive dysfunction (pocd) is a subtle cognitive dysfunction, especially postoperative memory impairment lasting for weeks or months. the underlying pathophysiological mechanism of pocd remain unclear. the aim of this study is to explore the epigenetic changes during perioperative period and its correlation with pocd in surgical patients.

the incidence of postoperative cognitive dysfunction (pocd) in elderly patients ranges widely from 16% to 21% and is associated with adverse outcomes. the exact cause of pocd remains unknown. extensive studies report that epigenetic modification, including the alteration of dna methylation and chromatin structure, plays an important part in the regulation of memory and learning. the present study thus hypothesize that epigenetic modification may increase the risk for pocd. the present study will enrolled the elderly patients (aged≥65) and young and middle-aged patents (aged 20-50) who are planning to undergo elective noncardiac surgery under general anesthesia. perioperative clinical characteristics of all patients will be recorded. participants enrolled will be evaluated for pocd with mini-mental state examination (mmse) on preoperative day, postoperative days 1. postoperative pain will be evaluated by the numerical rating scale (nrs). the patients' blood will be collected in the morning on the day before surgery and after surgery when they recover consciousness for the detection of concentration of 5-methylcytosine (5mc) and 5-hydroxymethylcytosine (5hmc) by enzyme-linked immunosorbent assays (elisa). the present study may help to find whether epigenetic changes will occur after surgical and anesthesia stress and will be an important factor for pocd in elderly patients.

Eligibility criteria:
inclusion criteria: •asa grade i to iii age \>65 bmi 18-28kg/m2 patients undergoing abdominal surgery,orthopedic surgery and spinal surgery exclusion criteria: * exclusion criteria: * do not consent, patients with mini mental state examination (mmse)score of ≤20 at screening severe heart,kidney or lung disfunction;unstable angina undergoing abdominal operation previously refuse to use pca unexpected surgical complication such as bleeding; psychiatric disorders; drug or alcohol abuse
genetic susceptibility to factor viii inhibitors

Conditions: Hemophilia

Summary: this international study will identify genetic factors that may influence the development of inhibitory antibodies in patients with hemophilia a after treatment with factor viii. bleeding episodes in patients with inhibitors are often more difficult to treat. previous research indicates that genetic factors play a role in the development of inhibitors. a better understanding of the influence of genes in this treatment complication may be helpful in predicting, treating or preventing inhibitors. people in families in which one or more members have severe factor viii deficiency and one or more have a history of an inhibitor may be eligible for this study. participants fill out a form with questions about the person's relationship to other family members taking part in the study. those with hemophilia provide a brief medical history, including hemophilia-related information, inhibitor history and the presence of other conditions such as hepatitis c and hiv. all participants have a blood sample taken for laboratory and research tests.

in collaboration with investigators of the hemophilia inhibitor genetic study (higs) multicenter study and the university of lund, university hospital, malmo, sweden, we propose to assess the role of genetic variants in the process of developing inhibitors to factor viii in persons with hemophilia. the discovery of genetic associations offers the potential to direct clinical management in order to prevent inhibitor development and improve clinical care in patients with inhibitors.

Eligibility criteria:
* inclusion criteria dna and relevant clinical data from properly consented hemophiliac subjects and family members (maximum estimated = 3500) will be provided to the lgd for genotyping and analysis. exclusion criteria no available subjects will be excluded to maximize power.

Keywords: hemophilia antibody mutations snp clotting
comparison of 12-day reverse hybrid therapy and 12-day standard triple therapy for helicobacter pylori infection

Conditions: Helicobacter Pylori Infection

Summary: reverse hybrid therapy is a one-step two-phase treatment for helicobacter pylori infection with less cost than standard triple therapy. whether reverse hybrid therapy can replace standard triple therapy as the recommended first-line treatment is unknown. the investigators compared the efficacy of 12-day reverse hybrid therapy and 12-day standard triple therapy in first-line treatment.

for this multicentre, single-blind, and randomized-controlled trial (rehytri study), the investigator recruited patients with h pylori infection. using a computer-generated randomization sequence, the investigator randomly allocated patients to either 12-day reverse hybrid therapy (pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg for the first 7 days, followed by pantoprazole 40 mg, amoxicillin 1 g for another 5 days; with all drugs given twice daily) or a 12-day standard triple therapy (pantoprazole 40 mg, clarithromycin 500 mg, amoxicillin 1 g for 12 days; with all drugs given twice daily) at a 1:1 ratio. our primary outcome was the eradication rate by intention-to-treat and per-protocol analyses.

Eligibility criteria:
inclusion criteria: * consecutive h pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis exclusion criteria: * previous h pylori-eradication therapy * ingestion of antibiotics or bismuth within the prior 4 weeks * patients with allergic history to the medications used * patients with previous gastric surgery * the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia) * pregnant women

Keywords: helicobacter pylori proton pump inhibitor eradication
severe sepsis/septic shock on admission to the general surgical icu

Conditions: Septic Shock; Multiple Organ Failure; Fatal Outcome

Summary: severe sepsis/septic shock are serious complications of infection with high morbidity and mortality. recent information showed that early and aggressive resuscitation may help improving survival and outcome especially the resuscitation within the first 3 hours. in surgical patients, either severe sepsis/septic shock bought them to the operating room or this sepsis might be found after surgery resulting in higher morbidity and mortality. not only knowledge management, others possible risk factors should also be identified and corrected for outcome improving. this prospective observational study will be done in 800 adult surgical patients admitting to the general surgical intensive care unit. incidence of severe sepsis/septic shock on admission along with risk factors associated with poor outcomes \[organ failure (aki, ali, pmi, liver failure, stroke), prolonged icu length of, stay, icu death\] will be recorded especially effect of amount and type of fluid replacement in the first 6 hours, 24, 48 and 72 hours after diagnosis. outcome as major organ failure, icu length of stay, icu, 28 and 90 days mortality will also be study.

consecutive severe sepsis/ septic shock patients who will be admitted to the general surgical icu of siriraj hospital, mahidol university, bangkok, thailand will be recruited to this study. apart from demographic data (age, sex, bmi, comorbidity), detail of septic shock and resuscitation (preoperative and intraoperative resuscitation), vasopressor and steroid used, type and amount of fluid, blood and blood component used and shock reversal time. complication associated with surgery, anesthesia and in icu will also recorded. clinical outcome as organ failure (stroke, pmi, aki, ards); ventilator day, icu and hospital length of stay, mortality (in icu, 28 and 90 days mortality) and cause of mortality will be carefully recorded

Eligibility criteria:
inclusion criteria: * adult (\> 18 years) surgical patient admitting to the general surgical icu * consent to this study exclusion criteria: * patient undergoing cardiothoracic surgery, neurosurgery and traumatic surgery * not consent to this study

Keywords: severe sepsis/septic shock organ failure aki pmi ali stroke icu death
a comparative analysis of arterial blood flow in unexplained infertility, tubal infertility and fertile groups

Conditions: Infertility

Summary: factors affecting the success of the treatment of infertility can evaluate before and after embryo transfer in two stages. most of the patients reach the embryo transfer stage. unfortunately, the investigators are able to intervene very few of the factors that will affect the success of the post-transfer. all factors and treatments that affect the implantation is vital to identify. basically, healthy vasculature is essential for a successful implantation. the investigators will try to understand relationship between vascular resistance and type of infertility. the investigators will examine whether the effect of the ovarian uterine and spiral artery resistance over infertility.

in this study the investigators will examine whether the alterations of doppler indices in the uterine, ovarian and spiral arteries can help to explain tubal or unexplained infertility as a standard screening method. patients in unexplained-tubal infertility groups were treated in our ivf clinic. patients will be invited to the hospital according to the criteria of the study. fertile patients will be selected according to the criteria for patients who have come for the annual smear control. the study hypothesis is that the resistance in ovarian, uterine and spiral artery doppler will be higher in cases with tubal and unexplained infertility as opposed to low resistance in fertile women.ovarian, uterine and spiral artery pulsatility index (pi = (peak systolic velocity - end diastolic velocity) / time averaged velocity and resistance index ( ri= (peak systolic velocity - end diastolic velocity) / peak systolic velocity ) will measure with doppler ultrasonography in the mid-luteal phase ( 21th day). measured values are to be compared.

Eligibility criteria:
inclusion criteria: * unsuccessful infertility treatment * normal prolactin levels * normal thyroid stimulation hormone levels * no ovarian or pelvic surgery history exclusion criteria: * to have systemic diseases * receive medical treatments which may influence the clearance or excretion of gonadotropins and sex steroids

Keywords: unexplained infertility tubal infertility pulsatility index resistance index fertile women
cardiac magnetic resonance imaging for detecting endothelial dysfunction

Conditions: Endothelial Dysfunction; Myocardial Perfusion Abnormalities; Cardiac MRI Perfusion With Vasomotor Stress; Diabetes

Summary: the goal of this research study is to demonstrate that cardiac perfusion mri with vasomotor stress may serve as a non-invasive and less risky imaging technique for detecting non-obstructive perfusion deficits and/or abnormalities in myocardial blood flow (mbf) in patients with endothelial dysfunction. this is a controlled study, which will enroll approximately 60 subjects (30 diabetics and 30 non-diabetics to serve as healthy controls), and will include male and non-pregnant females, between the ages 18-50 years. all eligible participants will sign an informed consent and will complete a lifestyle questionnaire. they will undergo blood work which includes: * 2-hour oral glucose tolerance test and fasting labs for glucose, insulin, c-peptide, hba1c, creatinine, and lipid panel. * urine albumin to creatinine ratio for microalbuminuria. * serum inflammatory markers: e-selectin, homocysteine, adma, vcam, il-6, tnfalpha, hs-crp and pai-1. after blood work, all participants will undergo cardiac mr perfusion imaging procedure with cold pressor test and adenosine stress test.


Eligibility criteria:
inclusion criteria: * age 18 to 50 years * should be able to sign an informed consent and hipaa agreement * 30 healthy, non-diabetic individuals * 30 diabetic individuals without documented coronary artery disease * diagnosed diabetics less than 5 years * hba1c less than 8.0 exclusion criteria: * children under 18 years and adults above 50 years * type 1 dm * lactating and pregnant females * bmi less than 35 * contraindication to mri such as pacemaker, defibrillator implants, etc. * allergy to mr (paramagnetic) contrast * history of angina, mi, or documented coronary artery disease * previous history of chf, cabg, angioplasty and stenting * history of valvular heart disease and congenital heart disease * history of peripheral vascular disease * history of cardiac arrythmias and anti-coagulation therapy * history of cerebro-vascular accidents or tia * history of active diabetic retinopathy and nephropathy * uncontrolled hypertension (systolic \> 170 and diastolic \>100 mm hg * end stage renal disease and patients on dialysis * hba1c of 8.0 * creatinine greater than 1.7 mg/dl * history of active gastrointestinal bleeding * history of iv drug use * chronic or current steroid treatment * growth hormone treatment

Keywords: endothelial dysfunction cardiac perfusion mri vasomotor stress cold pressor test adenosine stress
a four week study of azithromycin ophthalmic solution, 1% versus vehicle in subjects with blepharitis (p08636)

Conditions: Blepharitis

Summary: the purpose of this study is to compare the safety and efficacy of azithromycin ophthalmic solution, 1% versus vehicle over a four-week treatment period in treating the signs and symptoms of subjects with blepharitis and to evaluate the clinical course of the condition under study.


Eligibility criteria:
inclusion criteria: * have a current diagnosis of blepharitis * have a best corrected visual acuity (bcva), using corrective lenses if necessary, in both eyes of at least +0.7 * if female, are non-pregnant or non-lactating exclusion criteria: * have a concurrent acute hordeolum (stye) or chalazion * have inflammation of the ocular surface * have used artificial tears within 48 hours prior to visit 1 or anticipate using during the study * have had ocular surgery in the past 90 days or will require it during the study * unable to withhold the use of contact lenses during the study * have a known hypersensitivity to azithromycin, erythromycin, any other macrolide antibiotic, or any of the other ingredients in the study medication * have been diagnosed with ongoing glaucoma * unable to withhold the use of ocular cosmetic products within 48 hours prior to visit 1 and throughout the study * have a serious medical condition which could confound study assessments
prognosis of acute coronary syndrome in hiv-infected patients

Conditions: Coronary Heart Disease; HIV Infection

Summary: objectives: evaluate differences for mortality, morbidity and the cardiovascular risk factors between hiv and non-hiv patients with an acute coronary syndromes (acs) after a 3-years follow up.

background: there have been many cases of myocardial infarction reported in hiv-infected young adults treated with haart. little is known to date, concerning the outcome and prognostic factors of patients with acute coronary syndrome and hiv-infection. methods: prospective cohort study to compare the evolution and prognosis between hiv and non-hiv patients with an acs. duration of the study: two years for including patients. three years of follow-up 100 hiv-patients with acs and 200 non-hiv patients with acs will be included in the study. all patients will be included in the study from 30 intensive care unit of cardiology departments in france. results: to compare the incidence of total mortality, cardiovascular mortality (myocardial infarction, sudden death, cardiogenic shock, fatal stroke), morbidity (non fatal myocardial infarction, unstable angina, recurrence of ischemia, cardiac failure, non fatal stroke) and revascularization (percutaneous coronary intervention, coronary artery bypass graft surgery) during a 3-year follow-up between hiv and non-hiv patients with acs. univariate and multivariate analysis of predictive factors for cardiovascular events will be done.

Eligibility criteria:
inclusion criteria: * patients \> 18 year's old * man or woman hiv-infected for hiv 1 with or without highly active antiretroviral therapy * acute coronary syndromes (stemi, nstemi and unstable angina) exclusion criteria: * known atherosclerotic artery disease (mi, acs, pci, cabg, coronary stenosis, stroke, peripheral arteriopathy)

Keywords: acute coronary syndrome hiv infection prognosis coronary heart disease revascularization
1 week crossover dispensing study between two soft contact lenses

Conditions: Myopia

Summary: the objective of this investigation is to compare the visual clinical performance of a silicone hydrogel daily disposable investigational contact lenses to a hydrogel daily disposable commercially available contact lenses.

this is a prospective, bilateral, double masked (participant and investigator), randomized, cross-over dispensing study with 1 week wearing period in each arm by comparing visual acuity and subjective vision quality.

Eligibility criteria:
inclusion criteria: 1. are 8 to 18 years of age inclusive and have full legal capacity to volunteer; 2. have read and signed and dated the parental permission form (for those aged 16 and younger); participant has read, signed and dated the study information consent letter (if aged 17 or 18 years) or assent (aged 16 and younger); 3. are willing and able to follow instructions and maintain the appointment schedule; 4. are habitual daily wearers of spherical single vision soft contact lenses to correct for distance vision in each eye; 5. currently wears spherical soft contact lenses or myopia control soft lenses; 6. have a pair of wearable back-up spectacles; 7. are willing and able to wear contact lenses for at least 10 hours a day, 6 days a week while in the study; 8. are myopic with subjective refraction: -0.75d to -7.00d spherical, with an astigmatism ≤ -0.75d in each eye with maximum spherical equivalent anisometropia of 1.00d 9. are correctable to a visual acuity of +0.10 logmar or better (in each eye) with sphero-cylindrical subjective refraction; 10. have clear corneas with no corneal scars or any active ocular disease; 11. can be fit with the study contact lenses with a power between -0.75 and -7.00 ds; this translates to best corrected vision sphere refraction that vertexes to a cl power between -0.75 and -7.00 (inclusive) at screening visit. 12. demonstrate an acceptable fit with the study lenses. 13. demonstrate that they can safely and independently insert and remove contact lenses at the screening/fitting visit; exclusion criteria: 1. have taken part in another clinical research study within the last 14 days; 2. are currently habitual wearers of toric lenses. 3. have worn any rigid contact lenses or ortho-keratology lenses in the past 30 days 4. are an extended lens wearer (i.e., sleeping with their lenses) 5. are on ongoing atropine treatment for myopia control 6. have a difference of \> 1.0 d in best vision sphere subjective refraction between eyes; 7. have amblyopia and/or strabismus/binocular vision problem 8. have any known active ocular disease, allergies and/or infection; 9. have a systemic condition that in the opinion of the investigator may affect a study outcome variable; 10. are using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable; 11. have a known sensitivity to the diagnostic pharmaceuticals to be used in the study; 12. have undergone refractive error surgery or intraocular surgery; 13. are a member of core directly involved in the study.
open, prospective pilot study to obtain aerosol distribution in asthmatic patients using single photon emission computed tomography (spect) for comparison with functional imaging using computer methods

Conditions: Asthma

Summary: in this open prospective study, 6 well controlled asthmatic patients will undergo a high-resolution multi-slice computed tomography (ct) scan, lung function tests and a spect scan to obtain patient specific geometries of the central and peripheral small airways, patient specific boundary conditions and the in-vivo spatial distribution of inhaled aerosols.


Eligibility criteria:
inclusion criteria: 1. patients with well controlled asthma as defined by the current gina guidelines 2. male or female patients aged ≥18 years 3. patients with a documented positive response to the reversibility test (i.e. fev1 increase ≥ 12% and 200ml from baseline value after 4 puffs of 100 µg of inhaled salbutamol pmdi) within the 12 months preceding the screening visit or performed at screening visit after a wash-out of 2 days for long acting β2 agonists or a documented positive response to the methacholine challenge test 4. patients with a co-operative attitude 5. written informed consent obtained 6. patients maintained on stable respiratory medication for 4 weeks prior to visit 1 exclusion criteria: 1. patients who are pregnant or are breast-feeding 2. inability to carry out pulmonary function testing 3. diagnosis of copd as defined by the current gold guidelines 4. history of near fatal asthma 5. hospitalization due to exacerbation or respiratory infection of the airways 4 weeks prior to visit 1 6. current smokers or ex-smokers 7. patients with an uncontrolled disease or any condition that might, in the judgement of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study 8. cancer or any other chronic disease with poor prognosis and/or affecting patient status 9. bmi ≥ 35 kg/m2 10. patients treated with cpap or bipap 11. known active tuberculosis 12. a history of cystic fibrosis, central bronchiectasis or interstitial lung disease 13. a history of thoracotomy with pulmonary resection 14. patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study 15. patients who received any investigational new drug within the last 4 weeks prior to the screening visit
the immune reaction upon covid-19 vaccination in the belgian cancer population.

Conditions: Cancer

Summary: this study investigates the immune response in the cancer population in belgium being vaccinated with an approved vaccine types being authorized for use in belgium. this question needs to be answered to make sure that this vulnerable population is properly protected against possible sars-cov-2 infection and that vaccine administration is safe.

rationale: patients with cancer have an increased risk of adverse outcome of covid-19 and should be at high prioritisation for vaccination against sars-cov-2. the covid-19 vaccine trials have not included cancer patients as such, the efficacy and duration of immunity in patients with cancer are still unknown. keeping in mind that cancer patients are often immunocompromised, the immune response upon vaccination needs further investigation. the real-v is a prospective, multicenter cohort study. the humoral immunity response based on anti-sars-cov-2 igg antibodies upon covid-19 vaccination will be investigated in blood samples taken 4 months, 6 months and 12 months after (first) vaccine administration. potential factors that affect immunity, will be recorded, such as type and stage of cancer, anti-cancer treatment, concomitant medication,..to investigate the safety of different covid-19 vaccines, incidence and severity of systemic adverse events will be reported using an app based system answering questionnaires about specific vaccine related complaints.

Eligibility criteria:
inclusion criteria: * age of 18 years or older * oncological or hematological malignancy or history of it * life expectancy \> 3 months * ability to provide informed consent exclusion criteria: * women who are pregnant or breastfeeding * immune deficiency not related to cancer or cancer treatment * allergy (multiple); to be determined by physician